No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OII240719C17500
- 6.80
- 0.000.00%
15min DelayTrading May 7 11:12 ET
0.00High0.00Low
0.00Open6.80Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover4665.86%IV-7.29%PremiumJul 19, 2024Expiry Date8.71Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8570Delta0.0185Gamma3.85Leverage Ratio-37.3669Theta0.0000Rho3.30Eff Leverage0.0006Vega
Intraday
- 5D
- Daily
No Data
News
Notable Earnings After Wednesday's Close
Oceaneering Q2 2024 Earnings Preview
Oceaneering International (NYSE:OII) Is Doing The Right Things To Multiply Its Share Price
Oceaneering (OII) to Report Q2 Earnings: What's in Store?
Should You Be Adding Oceaneering International (NYSE:OII) To Your Watchlist Today?
Oceaneering Is Maintained at Buy by Citigroup
Comments
The modest level of insider ownership and lack of insider transactions in the last three months suggest alignment with shareholder interests. However, significant insider selling over the past year could be a red flag for investors.
Insiders At Oceaneering International Sold US$2.5m In Stock, Alluding To Potential WeaknessOceaneering International, Inc.'s transition from loss to profitability justifies its strong share price gain. Despite slowing gains, the company's future financial health remains crucial for shareholders.
Oceaneering International's respectable ROE is overshadowed by its high debt level. Investors should consider the company's performance potential in less favorable credit markets. High ROE without debt typically indicates a high-quality business.
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
18
7
Read more